Latest news with #SperoTherapeutics
Globe and Mail
30-06-2025
- Business
- Globe and Mail
Complicated Urinary Tract Infection (cUTI) Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Statistics, Revenue, Therapies, Companies by DelveInsight
Complicated Urinary Tract Infection (cUTI) companies are Pfizer, Novartis, Spero Therapeutics, Tetraphase Pharmaceuticals, Wockhardt, Venatorx Pharmaceuticals, Cubist Pharmaceuticals, Janssen, Allecra Therapeutics, Nabriva Therapeutics AG, La Jolla Pharmaceutical Company, MerLion Pharmaceuticals, PRA Health Sciences, Qilu Pharmaceutical, Meiji Seika Pharma and others. (Albany, USA) DelveInsight's " Complicated Urinary Tract Infection (cUTI) Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Complicated Urinary Tract Infection (cUTI), historical and forecasted epidemiology as well as the Complicated Urinary Tract Infection (cUTI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Complicated Urinary Tract Infection (cUTI) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Complicated Urinary Tract Infection (cUTI) market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Complicated Urinary Tract Infection (cUTI) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Complicated Urinary Tract Infection (cUTI) market. Some facts of the Complicated Urinary Tract Infection (cUTI) Market Report are: According to DelveInsight, Complicated Urinary Tract Infection (cUTI) market size is expected to grow at a decent CAGR by 2034. In June 2025, Menarini Group announced a clinical trial is to assess the pharmacokinetic (PK) and safety and tolerability of Vaborem ( fixed combination of meropenem and vaborbactam) in the paediatric population aged from 3 months to < 18 years with complicated urinary tract infection (cUTI) including acute pyelonephritis (AP) in need of hospitalisation and intravenous (IV) antibiotic administration. In June 2025, Venatorx Pharmaceuticals Inc. conducted a Phase 3 study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis. In June 2025, Rempex organized a study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). In April 2025, Rempex announced a study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). In April 2025, Menarini Group announced clinical trial is to assess the pharmacokinetic (PK) and safety and tolerability of Vaborem ( fixed combination of meropenem and vaborbactam) in the paediatric population aged from 3 months to < 18 years with complicated urinary tract infection (cUTI) including acute pyelonephritis (AP) in need of hospitalisation and intravenous (IV) antibiotic administration. In April 2025, Shionogi announced a study is to understand the pharmacokinetics (PK) of single and multiple doses of cefiderocol in children from birth to less than 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections. In the 7MM, nearly 1,000,000 cUTI incident cases progressed from uUTI in the year 2023, which is expected to increase during the forecast period (2024-2034). In the US, maximum number of cUTI cases were observed for the age group of 65-84 years, followed by =85 years. Among the EU4 and the UK, Germany recorded the highest number of diagnosed-incident cases of cUTI with approximately 26% cases in 2023, which is estimated to rise by 2034, at a CAGR of 0.6%. Japan accounted for around 800,000 cases of cUTI in 2023 caused due to Uropathogenic Escherichia coli, followed by 100,000 cases caused by Klebsiella pneumonia. Leading Complicated Urinary Tract Infection (cUTI) companies working in the market are Pfizer, Novartis, Spero Therapeutics, Tetraphase Pharmaceuticals, Wockhardt, Venatorx Pharmaceuticals, Cubist Pharmaceuticals, Janssen, Allecra Therapeutics, Nabriva Therapeutics AG, La Jolla Pharmaceutical Company, MerLion Pharmaceuticals, PRA Health Sciences, Qilu Pharmaceutical, Meiji Seika Pharma and others. Key Complicated Urinary Tract Infection (cUTI) Therapies expected to launch in the market are Ceftazidime –avibactam, Cefepime, LYS228, Eravacycline, Ertapenem, Levofloxacin, CXA-101, TBPM-PI-HBr, Doripenem, Meropenem- FL058, Piperacillin –tazobactam, aztreonam and nacubactam, cefepime and nacubactam, Sulopenem Etzadroxil/Probenecid, Meropenem, Cefepime-zidebactam (FEP-ZID), and others. On June 2023, Meiji Seika Pharma Co announced a Phase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AP). On May 2023, Wockhardt announced a Phase 3, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-ZID vs. meropenem in the treatment of hospitalized adults with Complicated Urinary Tract Infection or AP. Complicated Urinary Tract Infection (cUTI) Overview A complicated urinary tract infection (UTI) refers to an infection that occurs in the urinary tract and is associated with additional factors or conditions that make it more challenging to diagnose, treat, or resolve. These factors can include urinary tract abnormalities, obstruction, kidney stones, immunocompromised state, diabetes, pregnancy, catheterization, or antibiotic resistance. Complicated UTIs may involve not only the lower urinary tract (bladder and urethra) but also the upper urinary tract (kidneys and ureters). The complexity of these infections often necessitates a multidimensional approach, including targeted antibiotic therapy, identification and management of underlying factors, and close monitoring for potential complications. Complicated Urinary Tract Infection (cUTI) Market The Complicated Urinary Tract Infection (cUTI) market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Complicated Urinary Tract Infection (cUTI) market trends by analyzing the impact of current Complicated Urinary Tract Infection (cUTI) therapies on the market and unmet needs, and drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Complicated Urinary Tract Infection (cUTI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Complicated Urinary Tract Infection (cUTI) market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Complicated Urinary Tract Infection (cUTI) market in 7MM is expected to witness a major change in the study period 2020-2034. Complicated Urinary Tract Infection (cUTI) Epidemiology The Complicated Urinary Tract Infection (cUTI) epidemiology section provides insights into the historical and current Complicated Urinary Tract Infection (cUTI) patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Complicated Urinary Tract Infection (cUTI) market report also provides the diagnosed patient pool, trends, and assumptions. Complicated Urinary Tract Infection (cUTI) Drugs Uptake This section focuses on the uptake rate of the potential Complicated Urinary Tract Infection (cUTI) drugs recently launched in the Complicated Urinary Tract Infection (cUTI) market or expected to be launched in 2020-2034. The analysis covers the Complicated Urinary Tract Infection (cUTI) market uptake by drugs, patient uptake by therapies, and sales of each drug. Complicated Urinary Tract Infection (cUTI) Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Complicated Urinary Tract Infection (cUTI) market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Complicated Urinary Tract Infection (cUTI) Pipeline Development Activities The Complicated Urinary Tract Infection (cUTI) report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Complicated Urinary Tract Infection (cUTI) key players involved in developing targeted therapeutics. Complicated Urinary Tract Infection (cUTI) Therapeutics Assessment Major key companies are working proactively in the Complicated Urinary Tract Infection (cUTI) Therapeutics market to develop novel therapies which will drive the Complicated Urinary Tract Infection (cUTI) treatment markets in the upcoming years are Pfizer, Novartis, Spero Therapeutics, Tetraphase Pharmaceuticals, Wockhardt, Venatorx Pharmaceuticals, Cubist Pharmaceuticals, Janssen, Allecra Therapeutics, Nabriva Therapeutics AG, La Jolla Pharmaceutical Company, MerLion Pharmaceuticals, PRA Health Sciences, Qilu Pharmaceutical, Meiji Seika Pharma and others. Complicated Urinary Tract Infection (cUTI) Report Key Insights 1. Complicated Urinary Tract Infection (cUTI) Patient Population 2. Complicated Urinary Tract Infection (cUTI) Market Size and Trends 3. Key Cross Competition in the Complicated Urinary Tract Infection (cUTI) Market 4. Complicated Urinary Tract Infection (cUTI) Market Dynamics (Key Drivers and Barriers) 5. Complicated Urinary Tract Infection (cUTI) Market Opportunities 6. Complicated Urinary Tract Infection (cUTI) Therapeutic Approaches 7. Complicated Urinary Tract Infection (cUTI) Pipeline Analysis 8. Complicated Urinary Tract Infection (cUTI) Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Complicated Urinary Tract Infection (cUTI) Market Table of Contents 1. Key Insights 2. Executive Summary 3. Complicated Urinary Tract Infection (cUTI) Competitive Intelligence Analysis 4. Complicated Urinary Tract Infection (cUTI) Market Overview at a Glance 5. Complicated Urinary Tract Infection (cUTI) Disease Background and Overview 6. Complicated Urinary Tract Infection (cUTI) Patient Journey 7. Complicated Urinary Tract Infection (cUTI) Epidemiology and Patient Population 8. Complicated Urinary Tract Infection (cUTI) Treatment Algorithm, Current Treatment, and Medical Practices 9. Complicated Urinary Tract Infection (cUTI) Unmet Needs 10. Key Endpoints of Complicated Urinary Tract Infection (cUTI) Treatment 11. Complicated Urinary Tract Infection (cUTI) Marketed Products 12. Complicated Urinary Tract Infection (cUTI) Emerging Therapies 13. Complicated Urinary Tract Infection (cUTI) Seven Major Market Analysis 14. Attribute Analysis 15. Complicated Urinary Tract Infection (cUTI) Market Outlook (7 major markets) 16. Complicated Urinary Tract Infection (cUTI) Access and Reimbursement Overview 17. KOL Views on the Complicated Urinary Tract Infection (cUTI) Market 18. Complicated Urinary Tract Infection (cUTI) Market Drivers 19. Complicated Urinary Tract Infection (cUTI) Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Yahoo
28-06-2025
- Business
- Yahoo
While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership
Significant control over Spero Therapeutics by retail investors implies that the general public has more power to influence management and governance-related decisions A total of 25 investors have a majority stake in the company with 44% ownership Institutions own 20% of Spero Therapeutics Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Every investor in Spero Therapeutics, Inc. (NASDAQ:SPRO) should be aware of the most powerful shareholder groups. We can see that retail investors own the lion's share in the company with 54% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Meanwhile, institutions make up 20% of the company's shareholders. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. In the chart below, we zoom in on the different ownership groups of Spero Therapeutics. Check out our latest analysis for Spero Therapeutics Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. As you can see, institutional investors have a fair amount of stake in Spero Therapeutics. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Spero Therapeutics' earnings history below. Of course, the future is what really matters. Our data indicates that hedge funds own 6.8% of Spero Therapeutics. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. The company's largest shareholder is SR One Capital Management, LP, with ownership of 16%. In comparison, the second and third largest shareholders hold about 6.8% and 4.2% of the stock. A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Shareholders would probably be interested to learn that insiders own shares in Spero Therapeutics, Inc.. As individuals, the insiders collectively own US$3.5m worth of the US$162m company. This shows at least some alignment, but we usually like to see larger insider holdings. You can click here to see if those insiders have been buying or selling. The general public -- including retail investors -- own 54% of Spero Therapeutics. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions. Private equity firms hold a 16% stake in Spero Therapeutics. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public. It's always worth thinking about the different groups who own shares in a company. But to understand Spero Therapeutics better, we need to consider many other factors. Take risks for example - Spero Therapeutics has 3 warning signs (and 2 which can't be ignored) we think you should know about. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Business Insider
11-06-2025
- Business
- Business Insider
TD Cowen Remains a Hold on Spero Therapeutics (SPRO)
TD Cowen analyst Ritu Baral maintained a Hold rating on Spero Therapeutics (SPRO – Research Report) today. The company's shares closed today at $2.85. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Baral covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Vera Therapeutics. According to TipRanks, Baral has an average return of 7.1% and a 47.08% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Spero Therapeutics.
Yahoo
29-05-2025
- Business
- Yahoo
Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone
Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company's announcement of the successful completion of the pivotal Phase 3 PIVOT-PO trial for tebipenem HBr, an investigational oral antibiotic intended for use in treating complicated urinary tract infections. The Phase 3 study, conducted in collaboration with development partner GSK plc, effectively achieved its primary goal, proving that tebipenem HBr is not inferior to the intravenous antibiotic imipenem-cilastatin in treating adult hospitalized patients with cUTI. According to a press statement issued by Spero on May 28, tebipenem HBr may be the first oral carbapenem antibiotic that patients in the U.S. can get, potentially addressing an estimated 2.9 million annual cases of cUTIs. The full trial results will be submitted to a peer-reviewed journal for publication and presentation at a later scientific convention, with Spero and GSK intending to submit the findings to the FDA in the second half of 2025. While we acknowledge the potential of SPRO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SPRO and that has 100x upside potential, check out our report about the cheapest AI stock. Read More: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
28-05-2025
- Business
- Globe and Mail
Biotech Finds Mid-Week Success After Meeting Primary Endpoint
A biotech company based out of Massachusetts found a tremendous amount of success mid-week after the company announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), met its primary end point and will stop early for efficacy, according to a recent press release. Traders wasted no time snatching up shares of Spero Therapeutics Inc. (Nasdaq:SPRO), pushing the small cap to close the session up at $2.35/share (+244.57%). This move was a massive breakout from the multi-month downtrend this stock was stuck in since last year. Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. Copyright © 2025 All rights reserved. Republication or redistribution of content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. View more of this article on About Media, Inc.: Founded in 1999, is one of North America's leading platforms for micro-cap insights. Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders. is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals. Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today. Contact: Media, Inc.
